Design and characterization of chitosan/zeolite composite films — Effect of zeolite type and zeolite dose on the film properties

Barbosa, Gustavo P.; Debone, Henrique Selli; Severino, Patrícia; Souto, Eliana B.; Silva, Classius Ferreira da

doi:10.1016/j.msec.2015.11.034

Cited by 81 publications

(50 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, zeolites have become prominent regarding their use in the preparation of hydrogels for biomedical applications, due to their highly crystalline uniform microporous structures and ability to selectively adsorb various inorganic or organic molecules, such as for the enrichment and identification of peptides/proteins, the immobilization of enzymes for biosensing, wound healing, drug delivery, and several other biomedical applications . Zeolites have been incorporated into biopolymeric films for topical applications to promote burn wound healing . Zeolites embedded within polymeric scaffolds can enhance oxygen delivery to cells .…”

Section: Introductionmentioning

confidence: 99%

Low‐methoxyl pectin–zeolite hydrogels controlling drug release promote in vitro wound healing

Kocaaga

Kürkçüoğlu

Tatlıer

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

This study presents the design of novel hydrogel films, based on low-methoxyl (LM) pectin and NaA-or ZnA-zeolite particles, to serve as wound dressing materials with controlled drug delivery properties. We studied the effects of the preparation method of hydrogels, the amounts of crosslinker, drug and zeolite, and the type of cation in zeolites on the drug release mechanisms from the hydrogels. Ionic strengths of both film and external medium dictated the drug release behavior of the films, while the other parameters also played essential roles. NaAzeolite hydrogels prepared using membrane diffusion controlled system, could reach a drug release ratio of 86% within 5 h. The drug-free hydrogels displayed no cytotoxicity while supporting cell proliferation and migration. Our cost-effective LM pectin-zeolite hydrogels promise to be effective wound dressing materials with controlled drug delivery ability, transparency, good swelling properties, ability to hold fluids, good oxygen transmission rate, and biocompatibility.Pectin is a water soluble polysaccharide mostly extracted from citrus peels. It is a byproduct or waste product of fruit juice industry; therefore, it is easily available and cheap. It is mainly composed of linear chains of galacturonic acid residues. Pectin is referred to as low-methoxyl pectin (LM-pectin) in case the degree of esterification of the carboxylic acid groups is <50%. LM pectin forms three-dimensional (3D) network gels of Ca 2+ ion-bridged dimers to induce an "egg box shell" structure, 4 which makes it an Additional Supporting Information may be found in the online version of this article.

show abstract

Section: Introductionmentioning

confidence: 99%

Low‐methoxyl pectin–zeolite hydrogels controlling drug release promote in vitro wound healing

Kocaaga

Kürkçüoğlu

Tatlıer

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…A more uniform distribution was observed in a comparison with the sample treated with the application of zeolites, but the distribution was still discontinuous on the surface of the fiber. However, Barbosa et al . already reported that the chitosan film with zeolites formed two phases and lost its smooth microstructure and homogeneity as the zeolites were added.…”

Section: Resultsmentioning

confidence: 99%

“…These nanoparticles can, in turn, be incorporated into polymeric matrixes, often with strategies of simple addition that allow one to obtain antimicrobial polymers that are easily usable in industrial applications. This has been, in fact, an efficient strategy for extending the scope of their application …”

Section: Introductionmentioning

confidence: 99%

Thermal and antimicrobial evaluation of cotton functionalized with a chitosan–zeolite composite and microcapsules of phase‐change materials

Scacchetti

Pinto

Soares

2017

J of Applied Polymer Sci

View full text Add to dashboard Cite

Antimicrobial cotton was developed with silver zeolites (SZs). Three different application approaches for the cotton surface functionalization were followed: (1) SZ alone, (2) SZ combined with chitosan film, and (3) chitosan-zeolite (CS-SZ) composites previously synthesized by a gelation process with sodium tripolyphosphate. All finishes were applied to the textile materials through conventional pad-dry-cure processes, and the obtained results were then compared. The resulting materials were characterized with Fourier transform infrared spectroscopy, scanning electron microscopy with energy-dispersive X-ray spectroscopy, differential scanning calorimetry, IR thermography, and contact angle measurements, and the antimicrobial activity was evaluated. The results suggest that the application of CS-SZ should be recommended for the production of textiles with antibacterial properties because the materials showed activity against Escherichia coli, Staphylococcus aureus, Candida albicans, and Trichophyton rubrum. In addition, the finishing can be combined with the application of microcapsules of phase-change materials to obtain textiles with thermoregulating properties.

show abstract

“…Metal nanoparticles are commonly employed in medical imaging and diagnostics, but also as a theragnostic approach (i.e., combination of therapy and diagnosis). Besides, some metal nanoparticles exhibit antimicrobial activity being commonly applied in coatings for wound treatment [51,52].…”

Section: Production Methods Of Clinically Compliant Nanopharmaceuticsmentioning

confidence: 99%

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

et al. 2020

Self Cite

View full text Add to dashboard Cite

Due the implementation of nanotechnologies in the pharmaceutical industry over the last few decades, new type of cutting-edge formulations-nanopharmaceutics-have been proposed. These comprise pharmaceutical products at the nanoscale, developed from different types of materials with the purpose to, e.g., overcome solubility problems of poorly water-soluble drugs, the pharmacokinetic and pharmacodynamic profiles of known drugs but also of new biomolecules, to modify the release profile of loaded compounds, or to decrease the risk of toxicity by providing site-specific delivery reducing the systemic distribution and thus adverse side effects. To succeed with the development of a nanopharmaceutical formulation, it is first necessary to analyze the type of drug which is to be encapsulated, select the type matrix to load it (e.g., polymers, lipids, polysaccharides, proteins, metals), followed by the production procedure. Together these elements have to be compatible with the administration route. To be launched onto the market, the selected production method has to be scaled-up, and quality assurance implemented for the product to reach clinical trials, during which in vivo performance is evaluated. Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods. The first part of this study addressing "Nanopharmaceutics: Part I-Clinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU" has been published in Pharmaceutics. This second part complements the study with the discussion about the production scales and clinically compliant production methods of nanopharmaceutics.Nanomaterials 2020, 10, 455 2 of 16 funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1). Nanomaterials 2020, 10, x FOR PEER REVIEW 2 of 17European Commission aims to lead innovation towards the development of these nanopharmaceutics by launching several funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1).

show abstract

Design and characterization of chitosan/zeolite composite films — Effect of zeolite type and zeolite dose on the film properties

Cited by 81 publications

References 47 publications

Low‐methoxyl pectin–zeolite hydrogels controlling drug release promote in vitro wound healing

Low‐methoxyl pectin–zeolite hydrogels controlling drug release promote in vitro wound healing

Thermal and antimicrobial evaluation of cotton functionalized with a chitosan–zeolite composite and microcapsules of phase‐change materials

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

Contact Info

Product

Resources

About